| Robert A Zajac, MD | |
|
150 E Sonterra Blvd, Suite 170, San Antonio, TX 78258-4098 | |
| (210) 481-2800 | |
| (210) 481-2834 |
| Full Name | Robert A Zajac |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 43 Years |
| Location | 150 E Sonterra Blvd, San Antonio, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013907963 | NPI | - | NPPES |
| 131416308 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | H3973 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Texas Home Health Skilled Services | San antonio, TX | Home health agency |
| Brookdale Home Health San Antonio | San antonio, TX | Home health agency |
| Methodist Hospital Stone Oak | San antonio, TX | Hospital |
| Baptist Medical Center | San antonio, TX | Hospital |
| Peterson Regional Medical Center | Kerrville, TX | Hospital |
| Medina Regional Hospital | Hondo, TX | Hospital |
| Guadalupe Regional Medical Center | Seguin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Robert A Zajac Md Pa | 6204831498 | 5 |
News Archive
AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.
The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.
› Verified 9 days ago
| Entity Name | Robert A Zajac Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255357653 PECOS PAC ID: 6204831498 Enrollment ID: O20060921000404 |
News Archive
AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.
The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert A Zajac, MD Po Box 1346, San Antonio, TX 78295-1346 Ph: (210) 558-6288 | Robert A Zajac, MD 150 E Sonterra Blvd, Suite 170, San Antonio, TX 78258-4098 Ph: (210) 481-2800 |
News Archive
AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.
The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.
› Verified 9 days ago
Dr. Dennis Anthony Ruff, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 8307 Gault Ln, San Antonio, TX 78209 Phone: 210-798-5112 | |
Zarema J Singson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5223 Hamilton Wolfe Rd, San Antonio, TX 78229 Phone: 210-614-1234 Fax: 210-614-0952 | |
Sapna Raghunathan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 8300 Floyd Curl Dr, San Antonio, TX 78229 Phone: 210-450-9490 Fax: 210-450-6065 | |
Dr. Jonathan Edward Slovik, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 Medical Dr, San Antonio, TX 78229 Phone: 210-358-4000 Fax: 210-358-0647 | |
Mr. Paul Joseph Fanucchi, NP Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: Marianist Residence, 520 Fondham, San Antonio, TX 78228 Phone: 210-434-4157 Fax: 210-433-6005 | |
Socrates B Aramburu, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 Mccullough Ave, Suite 300, San Antonio, TX 78212 Phone: 210-271-3204 Fax: 210-222-2761 | |
David H White, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 6800 Ih 10 W, Ste 350, San Antonio, TX 78201 Phone: 210-616-0801 |